» Articles » PMID: 33120864

Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia

Abstract

The SLIT-ROBO axis plays an important role in normal stem-cell biology, with possible repercussions on cancer stem cell emergence. Although the Promyelocytic Leukemia (PML) protein can regulate expression in the central nervous system, little is known about SLIT2 in acute promyelocytic leukemia. Hence, we aimed to investigate the levels of SLIT2 in acute promyelocytic leukemia (APL) and assess its biological activity in vitro and in vivo. Our analysis indicated that blasts with transcript levels were associated with cell cycle arrest, while APL blasts displayed a more stem-cell like phenotype. In a retrospective analysis using a cohort of patients treated with all-trans retinoic acid (ATRA) and anthracyclines, high expression was correlated with reduced leukocyte count ( = 0.024), and independently associated with improved overall survival (hazard ratio: 0.94; 95% confidence interval: 0.92-0.97; < 0.001). Functionally, -knockdown in primary APL blasts and cell lines led to increased cell proliferation and resistance to arsenic trioxide induced apoptosis. Finally, in vivo transplant of Slit2-silenced primary APL blasts promoted increased leukocyte count ( = 0.001) and decreased overall survival ( = 0.002) compared with the control. In summary, our data highlight the tumor suppressive function of SLIT2 in APL and its deteriorating effects on disease progression when downregulated.

Citing Articles

LncRNA PGM5-AS1 inhibits non-small cell lung cancer progression by targeting miRNA-423-5p/SLIT2 axis.

Wang J, Ye J, Dang Y, Xu S Cancer Cell Int. 2024; 24(1):216.

PMID: 38902704 PMC: 11191156. DOI: 10.1186/s12935-024-03402-5.


M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.

Weinhauser I, Pereira-Martins D, Almeida L, Hilberink J, Silveira D, Quek L Sci Adv. 2023; 9(15):eadf8522.

PMID: 37058562 PMC: 11801312. DOI: 10.1126/sciadv.adf8522.


The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases.

Chin L, Kumana C, Kwong Y, Gill H Pharmaceutics. 2022; 14(9).

PMID: 36145693 PMC: 9504237. DOI: 10.3390/pharmaceutics14091945.


DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.

Cendrowicz E, Jacob L, Greenwald S, Tamir A, Pecker I, Tabakman R J Exp Clin Cancer Res. 2022; 41(1):97.

PMID: 35287686 PMC: 8919572. DOI: 10.1186/s13046-022-02256-x.


Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells.

Wang J, Peng X, Yang D, Guo M, Xu X, Yin F J Cell Mol Med. 2021; 26(2):563-569.

PMID: 34910369 PMC: 8743673. DOI: 10.1111/jcmm.17128.


References
1.
Liu Y, Jiang S, Yang Y, Xu H, Liu J, Wang X . USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 2011; 62(1):229-35. DOI: 10.1007/s12013-011-9287-0. View

2.
Meng S, Luo M, Sun H, Yu X, Shen M, Zhang Q . Identification and characterization of Bmi-1-responding element within the human p16 promoter. J Biol Chem. 2010; 285(43):33219-33229. PMC: 2963359. DOI: 10.1074/jbc.M110.133686. View

3.
Gaillard C, Surianarayanan S, Bentley T, Warr M, Fitch B, Geng H . Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia. Blood Adv. 2018; 2(19):2462-2466. PMC: 6177650. DOI: 10.1182/bloodadvances.2018018929. View

4.
Verhaak R, Wouters B, Erpelinck C, Abbas S, Beverloo H, Lugthart S . Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2008; 94(1):131-4. PMC: 2625407. DOI: 10.3324/haematol.13299. View

5.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View